Investigational drug · Phase 2
ARGX-121
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Immunoglobulin A Nephropathy (IgAN).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ARGX-121"
First trial start
2026
Nov 5, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ARGX-121", any sponsor or status.
Conditions studied
As listed on its trial records.
- Immunoglobulin A Nephropathy (IgAN)
Approved drugs for the same conditions: IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "ARGX-121" as an intervention, largest first.
- A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgANPivotal-lookingRecruiting
argenxargenx (ARGX)
NCT07773727 · 120 participants (planned) · Start Nov 5, 2026 · Primary completion Oct 29, 2029
Drug: ARGX-121; Placebo · For: Immunoglobulin A Nephropathy (IgAN)
Sites: Valencia, California; Miami, Florida; Pembroke Pines, Florida · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Immunoglobulin A Nephropathy (IgAN)
- FelzartamabPhase 38 trials
Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease
- TelitaciceptRC18, RC18-LPhase 38 trials
RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease
- FUB523zigakibart, BION-1301Phase 36 trials
Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)
- HS-10542Phase 22 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from argenx.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.